{
      "Rank": 413,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Selected SLE patients were randomly divided into treated group and control group. In the treated group, 100-300 million allogeneic human umbilical cord derived mesenchymal stem cells were infused intravenously for one SLE patient. The possible adverse events, including immediately after mesenchymal stem cells infusions, as well as the long-term safety profiles were observed."
      ],
      "ArmGroupInterventionName": [
            "Biological: mesenchymal stem cells"
      ],
      "ArmGroupLabel": [
            "mesenchymal stem cells"
      ],
      "ArmGroupType": [
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03219801"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This study is to evaluate the safety and efficacy of human umbilical cord derived mesenchymal stem cells transplantation in systemic lupus erythematosus."
      ],
      "BriefTitle": [
            "Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus"
      ],
      "CentralContactEMail": [
            "june_luck@126.com"
      ],
      "CentralContactName": [
            "Jun Zhang, Master"
      ],
      "CentralContactPhone": [
            "86-311-85917384"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact"
      ],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "December 30, 2019"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Systemic Lupus Erythematosus"
      ],
      "ConditionAncestorId": [
            "D000003240",
            "D000001327",
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Connective Tissue Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC17",
            "BC20",
            "All"
      ],
      "ConditionBrowseBranchName": [
            "Skin and Connective Tissue Diseases",
            "Immune System Diseases",
            "All Conditions"
      ],
      "ConditionBrowseLeafAsFound": [
            "Systemic Lupus Erythematosus"
      ],
      "ConditionBrowseLeafId": [
            "M10329",
            "M5616",
            "M3781",
            "M9352"
      ],
      "ConditionBrowseLeafName": [
            "Lupus Erythematosus, Systemic",
            "Connective Tissue Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000008180"
      ],
      "ConditionMeshTerm": [
            "Lupus Erythematosus, Systemic"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "To ensure that all patients of systemic lupus erythematosus (SLE) completed 6-months follow-up, twenty SLE patients ranging from 14 to 60 years old were enrolled in this trial. Participants matched with the inclusion criteria were allocated randomly into two groups:Human Umbilical Cord Derived Mesenchymal Stem Cells (hUC-MSCs) treated group and control group. Clinical trials are being increasingly established to investigate the therapeutic potential of these cells for SLE. The aim of the present study is to investigate safety and efficacy of vein infusion of allogeneic hUC-MSCs in patients with SLE."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nDiagnosis of SLE(Systemic lupus erythematosus) from American College of Rheumatology(ACR) according to established criteria in 1997\nAge from 14 to 60 years\nNo serious infection or acute hemorrhage\nLeft ventricular ejection fraction (LVEF)\u2265 50%\nBoth transaminase and serum creatinine level are more than twice times the upper limit of normal\nNo acute infectious diseases.\nUnderstanding and willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\nPatients with SLE have to be disqualified from this study if any of the following is applicable:\n\nSLE(Systemic lupus erythematosus) with severe infection.\nSevere heart attack, liver and kidney disease following serious complications\nPatients with allergic constitution.\nPregnancy and breastfeeding women.\nAccompanied by malignant tumors or other malignant disease\nPatients as participant in the other clinical text\nPatients with active tuberculosis, acute sever hepatitis or infectious period of diseases."
      ],
      "EnrollmentCount": [
            "10"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "mesenchymal stem cells"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "SLE patients in the treated group were given human umbilical cord derived mesenchymal stem cells by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1, 3 and 6months were evaluated respectively the curative effect."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "mesenchymal stem cells"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [
            "Not yet recruiting"
      ],
      "LastUpdatePostDate": [
            "July 18, 2017"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "July 13, 2017"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Hebei Medical University"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Shijiazhuang"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "China"
      ],
      "LocationFacility": [
            "the First Hospital of Hebei Medical University"
      ],
      "LocationState": [
            "Hebei"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "050031"
      ],
      "MaximumAge": [
            "60 Years"
      ],
      "MinimumAge": [
            "14 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Evaluation of Safety and Efficacy in Patients With Systemic Lupus Erythematosus by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Hebei Medical University"
      ],
      "OrgStudyId": [
            "17277787D-SLE"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "The First Hospital of Hebei Medical University",
            "The First Hospital of Hebei Medical University",
            "The First Hospital of Hebei Medical University",
            "The First Hospital of Hebei Medical University",
            "The First Hospital of Hebei Medical University",
            "The First Hospital of Hebei Medical University",
            "The First Hospital of Hebei Medical University",
            "The First Hospital of Hebei Medical University",
            "The First Hospital of Hebei Medical University",
            "The First Hospital of Hebei Medical University",
            "The First Hospital of Hebei Medical University"
      ],
      "OverallOfficialName": [
            "Baoyong Yan, Doctor",
            "Qingchi Liu Liu, Doctor",
            "Quanhai Li, Doctor",
            "Xiaohui Jia, Doctor",
            "Xianyun Wang, Doctor",
            "Fan Zhang, Bachelor",
            "Yang Shen, Master",
            "Bing Ma, Master",
            "Wanyi Yin, Master",
            "Dan Zhao, Master",
            "Bojian Sun, Master"
      ],
      "OverallOfficialRole": [
            "Study Chair",
            "Study Director",
            "Study Director",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Unknown status"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Early Phase 1"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 30, 2018"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "The recovery of immunologic function is evaluated by complement levels (g/L) in peripheral blood."
      ],
      "PrimaryOutcomeMeasure": [
            "The change of Complement levels(C3 and C4) in peripheral blood"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Post cell transplantation: 1, 3, 6 months"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Hebei Medical University"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Quanhai Li"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Director of Cell Thearpy Center, the First Hospital of HeibeiMU"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "The change of inflammation is evaluated by erythrocyte sedimentation rate.",
            "C-reactive protein is an acute phase reactants. It can be moderately increased in in peripheral blood of SLE patients.",
            "Adverse reaction includes temperature changes(\u2103), the change of blood pressure(mmHg) and allergic reaction.These measurements were associated with the safety of the intervention."
      ],
      "SecondaryOutcomeMeasure": [
            "Erythrocyte sedimentation rate",
            "C-reactive protein",
            "adverse reaction"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Post cell transplantation: 1, 3, 6 months",
            "Post cell transplantation: 1, 3, 6 months",
            "Post cell transplantation: 1, 3, 6 months"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "August 1, 2017"
      ],
      "StartDateType": [
            "Anticipated"
      ],
      "StatusVerifiedDate": [
            "July 2017"
      ],
      "StdAge": [
            "Child",
            "Adult"
      ],
      "StudyFirstPostDate": [
            "July 18, 2017"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "July 10, 2017"
      ],
      "StudyFirstSubmitQCDate": [
            "July 13, 2017"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}